Taysha Gene Therapies, Inc.

tayshagtx.com

What Do They Do?

Develops AAV-based gene therapies for severe central nervous system diseases, with its lead program aimed at treating Rett syndrome in patients.

How Do They Make Money?

Revenue comes from its Astellas arrangements, which include an exclusive option to license intellectual property and research and development work for Astellas. The filing describes no product sales.

FY2025 revenue

Who Are Their Customers?

Astellas is the customer under arrangements covering an exclusive option to license intellectual property and research and development activities.

Do Revenues Turn Into Profits?

No. It lost $109M in FY2025.

Operating income, FY2025

−1131% of revenue

▲ +21% (Loss) vs FY2024 (−$91.5M, −1098%)

Net income, FY2025

−1115% of revenue

▲ +22% (Loss) vs FY2024 (−$89.3M, −1072%)

Free cash flow, FY2025

−960% of revenue

▲ +15% (Loss) vs FY2024 (−$81.6M, −979%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −100%; vs $2M in Q2 FY2025
Net income: ▲ +73% (Loss); vs −$26.9M in Q2 FY2025

Aug 11, 2026 Completed dosing in the REVEAL pivotal and ASPIRE trials Completed dosing of 17 patients in REVEAL and four in ASPIRE; topline data and FDA feedback on the BLA pathway are expected in the first half of 2027.

Comments